12 November 2021 (Friday) - ASH Update

The nice people at the American Society of Hematology sent their update today. This one was on MDS and Myeloproliferative Neoplasms. Like much of their output it isn’t really aimed at me, but I was glad to have a look at it; I picked up one or two snippets (as I usually do).

Little and often” is the way with CPD…

Here are the highlights in MDS and myeloproliferative neoplasms:

Germline Variants in DNA Repair Pathway Genes May Trigger Familial MPNs Recent findings published in Blood Advances suggest these variants should be incorporated in diagnostic workups.
New Prognostic Model Outperforms Established Predictive Models in MDS Researchers reported that a newly developed personalized prediction model comprising clinical and genomic data performed better than established predictive models in patients with MDS.
Reduced-Intensity Conditioning Transplant Superior to Continuous 5-Azacitidine in Older Patients With MDS In older patients with advanced MDS, reduced-intensity conditioning alloHCT improved event-free survival compared with continuous 5-azacitidine therapy.


No comments:

Post a Comment